CLOs on the Move

Ambulatory Care Affiliates

www.acamanagement.com

 
Ambulatory Care Affiliates, Ltd. is a New Albany, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

SEIU 775 Benefits Group

Holistic training, health and retirement benefits for Washington states professional home caregivers.

Sameday Health

Sameday Health is dedicated to healthcare as a complete experience, not simply a service. Our purpose is to create healthcare that centers around the client, combining a human approach with intuitive technology. We offer quality, personalized care wherever you are including in our clinics or at your door.

LunchboxWax

Welcome to LunchboxWax, a place that proves that chic and cheeky do, in fact, co-exist. Our refined, unique speed-waxing technique means smooth skin is just minutes away. You won`t be at LunchboxWax long, but while you`re here, you`ll feel like you`re the only one who matters. Because to us, you are. Great things happen when you choose to do one thing and do it well. That`s why we believe our Lunchbox waxologists are the best. They`re committed to their craft and your happiness. It`s all they do. Just like we handpick our waxologists, we assemble other experts to make our business run as smooth as your skin after a LunchboxWax Brazilian. Yep, we just said that. Our business formula works, and we`re excited to share it through the LunchboxWax Franchise System.

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.